{
  "meta": {
    "title": "Diabetes_Part_1",
    "url": "https://brainandscalpel.vercel.app/diabetes-part-1-da54e54d.html",
    "scrapedAt": "2025-11-30T11:12:51.743Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 2</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 3</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">1,2,3</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">1,2,3,4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient presents with new-onset diabetes mellitus. Which of the following endocrinopathies are known to increase the risk of diabetes mellitus?<br>1. Cushing syndrome<br>2. Acromegaly<br>3. Hyperthyroidism<br>4. Pheochromocytoma</span></p>",
      "unique_key": "DT1186900",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186900,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>All the above-mentioned endocrine disorders are known to cause secondary diabetes mellitus.</p>\r\n<ul>\r\n<li>Increased levels of cortisol characterise Cushing syndrome. Cortisol has <strong>anti-insulin action</strong> and <strong>stimulates gluconeogenesis</strong>, resulting in hyperglycemia.</li>\r\n<li>Hypersecretion of growth hormones after puberty results in acromegaly. Growth hormone also has<strong> insulin-antagonistic actions</strong>, increasing glycogenolysis and gluconeogenesis, which results in hyperglycemia.</li>\r\n<li>Pheochromocytoma is characterised by high levels of catecholamines, which a <strong>diabetogenic hormones</strong>. Catecholamines impair insulin secretion and increase glycogenolysis and gluconeogenesis.</li>\r\n<li>Hyperthyroidism causes hyperglycemia by <strong>increasing insulin clearance</strong> and producing abnormalities in the processing of insulin.</li>\r\n</ul>\r\n<p>Hence, all these conditions can predispose to the development of secondary diabetes mellitus.</p>",
      "correct_choice_id": 4,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 4</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 4</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An 18-year-old non-obese male on routine health checkup was found to have a high fasting blood glucose level. Which of the following features supports a diagnosis of MODY rather than Type 1 Diabetes?<br>1. Low insulin requirement<br>2. Absence of microvascular complications<br>3. No episodes of Diabetes ketoacidosis<br>4. Absence of anti-GAD antibody positivity</span></p>",
      "unique_key": "DT1186901",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186901,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>MODY patients have been observed to have the same risk for microvascular complications, though the risk of macrovascular complications is decreased compared to type 2 Diabetes.</p>\r\n<p>Maturity-onset diabetes of the young (MODY) is a subtype of DM characterised by <strong>autosomal dominant inheritance,</strong> early onset of hyperglycemia (usually &lt;25 years; sometimes in the neonatal period), and impaired insulin secretion.</p>\r\n<p><strong>Clinical features favouring MODY:</strong></p>\r\n<ul>\r\n<li>Strong family history</li>\r\n<li>Low insulin requirement (&lt;0.5 units/kg/day)</li>\r\n<li>No episodes of DKA</li>\r\n<li><strong>Absence of autoantibodies</strong></li>\r\n<li>Detectable C-peptide levels after 2-3 years of diagnosis<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509183339633f-0e17-43b3-8efc-590e5f21df3a.png\"></li>\r\n</ul>",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Fasting blood glucose > 126 mg/dl</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Fasting blood glucose > 92 mg/dl</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">2-hour OGTT value > 140 mg/dl</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">2-hour OGTT value > 180 mg/dl</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">According to IADPSG criteria, which of the following blood glucose values is diagnostic of gestational diabetes?</span></p>",
      "unique_key": "DT1186902",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186902,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>According to IADPSG criteria, a fasting blood glucose level &gt; 92 mg/dl is diagnostic of gestational diabetes mellitus.</p>\n<ul>\n<li>Screening for GDM is a routine part of prenatal care.</li>\n<li>First trimester screening is performed for high-risk women according to ADA, while ACOG advocates universal screening for all women</li>\n<li>The diagnosis of Gestational Diabetes mellitus is made if either one of the following is satisfied:\n<ul>\n<li><strong>Fasting blood glucose &gt; 92 mg/dl</strong></li>\n<li>1 hr post OGTT &gt; 180 mg/dl</li>\n<li>2 hr post OGTT &gt; 153 mg/dl <em>(Option C, D ruled out)</em></li>\n</ul>\n</li>\n<li>If fasting blood glucose is more than 126 mg/dl or the 2-hour post glucose load value is &gt; 200 mg/dl, the diagnosis of overt diabetes mellitus is made. <em>(Option A ruled out.)</em></li>\n<li>GDM increases the risks of maternal and neonatal complications associated with pregestational diabetes.</li>\n<li>Treating GDM reduces the risk of preeclampsia, birth weight &gt;400 g, and shoulder dystocia.</li>\n</ul>",
      "correct_choice_id": 22,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Occurs after the age of 30 years</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Requires insulin from the time of diagnosis</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-GAD antibody positivity</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Complication rate similar to Type 1 Diabetes</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a characteristic feature of Latent Autoimmune Diabetes in Adults?</span></p>",
      "unique_key": "DT1186903",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186903,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Patients with Latent Autoimmune Diabetes in Adults do not require insulin at the time of diagnosis; they may respond to oral hypoglycemic drugs initially.</p>\n<p><strong>Latent Autoimmune Diabetes in Adults (LADA):<br /> </strong></p>\n<ul>\n<li>If a person develops hyperglycemia in their early 30s to late 40s and is initially managed with oral hypoglycemic agents, but eventually becomes insulin-dependent, Latent Autoimmune Diabetes in Adults should be suspected.</li>\n<li>The <strong>presence of pancreatic autoantibodies</strong>, such as anti-GAD antibodies, further supports the diagnosis.</li>\n<li>These patients typically do not show features of insulin resistance.</li>\n<li>LADA patients do not require insulin for at least 6 months after diagnosis.</li>\n<li>Early use of insulin may prolong &beta;-cell function, as well as prevent a period of sustained hyperglycemia that could initiate chronic complications.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025091852b70278-6724-4ba3-824e-6bb32d309a5f.png\"></li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<p>Immunology of Diabetes Society criteria for diagnosis of LADA</p>\n<ul>\n<li>Age at diagnosis &gt; 30 years</li>\n<li>Presence of autoantibodies against islet antigens</li>\n<li>Not requiring insulin for at least 6 months after diagnosis of DM</li>\n</ul>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Linagliptin</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Actrapid insulin</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Glimepiride</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old man with diet-controlled type 2 diabetes mellitus is found to have a serum creatinine of 3.0 mg/dl. Which of the following medications should be avoided in this patient?</span></p>",
      "unique_key": "DT1186904",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186904,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Metformin is contraindicated in patients with<strong> renal insufficiency</strong> due to the risk of <strong>lactic acidosis</strong>. Serum creatinine of 3 mg/dl indicates renal dysfunction; hence should be avoided in this patient.</p>\n<ul>\n<li>Metformin, a biguanide, is the OHA of choice for diabetes.</li>\n<li>Acts by improving insulin sensitivity through mechanisms involving hepatic gluconeogenesis and improved muscle glucose utilisation.</li>\n<li>Increases peripheral utilisation of glucose by<strong> upregulating GLUT-4 receptors</strong>.</li>\n</ul>\n<p><strong>Contraindication:</strong></p>\n<ul>\n<li>It is contraindicated in subjects with renal failure, hepatic failure and heart failure due to an association with <strong>lactic acidosis.</strong></li>\n<li>In such patients, if <strong>GFR &lt; 30ml/min</strong>, metformin is not advised.</li>\n</ul>\n<p><strong>Advantages:</strong></p>\n<ul>\n<li>Rarely causes hypoglycemia</li>\n<li>Do not cause weight loss or result in modest weight loss</li>\n<li>Causes HbA1c reduction of 1-2%</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Linagliptin (Option A): Linagliptin is a dipeptidyl peptidase IV inhibitor. It </strong>can be used without dose modification in renal dysfunction. ction</p>\n<p><strong>Actrapid insulin (Option B): </strong>Actrapid, the regular insulin, is safe in all stages of CKD. Most insulin preparations are not contraindicated in patients with renal insufficiency.</p>\n<p><strong>Glimepiride (Option C): </strong>Glimepiride is a sulphonylurea which requires dose reduction in renal failure due to increased risk of hypoglycemia, but is not contraindicated.</p>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">They act at the PPAR-&gamma; receptor site, promoting binding as a heterodimer with the retinoid X-receptor to DNA</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibitor of oxidative phosphorylation</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">They act by reducing peripheral insulin sensitivity</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of the hepatic glucokinase enzyme</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old man is started on pioglitazone due to poor glycemic control, despite being on the maximum tolerated dose of metformin.. Which of the following describes the mechanism by which pioglitazone improves glycemic control?</span></p>",
      "unique_key": "DT1186905",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186905,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Pioglitazone improves glycemic control by activating <strong>PPAR-&gamma; receptors</strong>, leading to enhanced insulin sensitivity.</p>\r\n<ul>\r\n<li>Pioglitazone is a PPAR-&gamma; agonist that acts by binding to the PPAR-&gamma; receptor, which binds to a promoter region of DNA in tandem with the retinoid X-receptor.</li>\r\n<li>This leads to the <strong>upregulation</strong> of a number of enzymes concerned with lipid metabolism, resulting in decreased levels of circulating fatty acids.</li>\r\n<li>The fall in free fatty acids causes a reduction in hepatic insulin resistance, a rise in adiponectin and <strong>improved peripheral insulin sensitivity</strong>. <em>(Option C ruled out.)</em></li>\r\n</ul>\r\n<p><strong>Side effects of Pioglitazone:</strong></p>\r\n<ul>\r\n<li>Weight gain</li>\r\n<li>Reduction in the hematocrit and an increase in plasma volume.</li>\r\n<li>Peripheral oedema</li>\r\n<li>Increased risk of CHF</li>\r\n</ul>\r\n<p><strong>Contraindications:</strong></p>\r\n<ul>\r\n<li>Hepatic insufficiency</li>\r\n<li>CHF (class III or IV).</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Inhibitor of oxidative phosphorylation (Option B): </strong>Oxidative phosphorylation plays a crucial role in the later stages of aerobic glucose metabolism. Inhibition of this process can impair glucose utilisation and contribute to hyperglycemia. Pioglitazone, however, does not inhibit oxidative phosphorylation.</p>\r\n<p><strong>Inhibition of the hepatic glucokinase enzyme (Option D):</strong> Inhibition of glucokinase would reduce glucose utilisation, which is undesirable in diabetes. Thus, pioglitazone does not inhibit glucokinase; instead, it lowers glucose levels by its insulin-sensitising effects.</p>",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">A BMI of 23</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">High circulating insulin level</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">HLA type DR-3</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Positive islet-cell antibodies</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old man presents with excessive thirst, polyuria and unintentional weight loss. Urine analysis showed the presence of ketone bodies. Which of the following findings would suggest a diagnosis of Type 2 DM rather than Type 1?</span></p>",
      "unique_key": "DT1186906",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186906,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>High circulating insulin levels suggest Type 2 diabetes, as insulin resistance is the primary issue, whereas Type 1 diabetes typically presents with low or absent insulin due to autoimmune &beta;-cell destruction.</p>\n<p><strong>Type 1 DM:</strong></p>\n<ul>\n<li>Type-1 diabetes mellitus is an <strong>autoimmune disorder </strong>characterised by the presence of <strong>autoantibodies to the islet cell</strong> (ICA), insulin (IAA) or glutamic acid dehydrogenase (GAD).</li>\n<li>This leads to immune-mediated destruction of the pancreatic beta cells and insulin deficiency.</li>\n<li>It is associated with <strong>HLA DR-3 or DR-4.</strong></li>\n<li>Around 30% patients with Type 1 DM may present with DKA.</li>\n</ul>\n<p><strong>Type 2 DM:</strong></p>\n<ul>\n<li><strong>Insulin resistance </strong>and abnormal insulin secretion are central to the development of type 2 DM.</li>\n<li>Patients with type 2 diabetes more commonly have a high <strong>BMI &gt; 25.</strong></li>\n<li>The presence of ketosis/ketoacidosis is extremely rare in Type 2 DM, while<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918e8c7f7c2-0662-4da9-aa01-7ddded5ce76c.png\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918e28e2f4c-6946-44ba-9b15-491ebf60cbb6.png\"></li>\n</ul>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduce her dose of BD mixed insulin by 50%</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduce her dose of BD mixed insulin by 20%</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Check a random cortisol to rule out Addison's disease</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Change her to a basal bolus regime</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 29-year-old 3rd gravida with gestational diabetes mellitus was brought ER after she collapsed while shopping. Currently, she is on mixed insulin, taken twice daily, and her recent fasting glucose levels have been between 80-90 mg/dL. Her blood glucose level at the time of arrival at the ER was 56 mg/dl. Which of the following represents the most appropriate management for this patient?</span></p>",
      "unique_key": "DT1186907",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186907,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>For a pregnant woman with GDM who develops hypoglycemia on twice daily mixed insulin, switching to a basal-bolus regimen is the most appropriate option for safer, better glycemic control.</p>\r\n<p>A basal bolus regimen would give:</p>\r\n<ul>\r\n<li><strong>More flexibility </strong>in varying insulin doses</li>\r\n<li>Reduces the risk of overcorrection, thus lowering the chances of hypoglycemia</li>\r\n<li>Better glycemic control</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Reduce her dose of BD mixed insulin by 50% (Option A):</strong> A 50% reduction in her dose can result in overcorrection, resulting in poor glycemic control.</p>\r\n<p><strong>Reduce her dose of BD mixed insulin by 20% (Option B): </strong>If the dose is reduced by 20%, it may help, but lacks dosing flexibility. Hence is not the appropriate management.</p>\r\n<p><strong>Check a random cortisol to rule out Addison's disease (Option C):</strong> Although Addison's disease can lead to hypoglycemia, it is very unlikely in this case because the hypoglycemia has resulted from high doses of insulin use despite her recent low FBS values. Also, there are no clinical features suggestive of adrenal insufficiency.</p>",
      "correct_choice_id": 74,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Minor background retinopathy</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Hb A1C 9.4%</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Not on folic acid supplementation</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Microalbumin level of 6 mg excretion in 24 hours</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25-year-old woman with type 1 diabetes mellitus presents for a routine follow-up and reports being keen on becoming pregnant. Which of the following factors would most necessitate the need to delay pregnancy?</span></p>",
      "unique_key": "DT1186908",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186908,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>An HbA1c of 9.4% reflects poor glycemic control, which significantly increases the risk of congenital abnormalities, miscarriages, and obstetric complications. Thus delaying pregnancy, till a better glycemic control is crucial.</p>\n<ul>\n<li>Pregnancy in Type-1 DM is associated with a two- to threefold increase in <strong>congenital abnormalities</strong> when compared with the background population.</li>\n<li>It is also associated with <strong>higher neonatal morbidity</strong> and <strong>mortality</strong> and <strong>higher operative delivery rates</strong> compared to gestational diabetes.</li>\n<li>Prepregnancy counselling to bring the Hb A1c to near-normal levels is associated with better pregnancy outcomes.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Minor background retinopathy (Option A): </strong>Diabetic retinopathy can progress during pregnancy, and the eyes must be checked at least once each trimester; if there is progression that is sight-threatening, then the patient should be referred to an ophthalmologist. Background retinopathy would not be a contraindication to pregnancy.</p>\n<p><strong>Not on folic acid supplementation (Option C): </strong>While women with diabetes are advised to take 5 mg folic acid daily to reduce the risk of neural tube defects, the absence of supplementation is not a reason to delay pregnancy. Folic acid can be started as soon as conception is planned, though ideally, it should be taken for at least 3 months prior.</p>\n<p><strong>Microalbumin level of 6 mg excretion in 24 hours (Option D): </strong>This microalbumin level is within normal limits. Nephropathy can also progress during pregnancy, but microalbuminuria would not be a contraindication to pregnancy and nor would sensory neuropathy.</p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulinoma</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Reactive Hypoglycemia</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Illicit use of sulphonylureas</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Illicit use of insulin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 24-year-old medical student presents with recurrent episodes of collapse, typically occurring during stressful situations. She recently experienced two such episodes while witnessing cardiac arrests during her Emergency Department rotation. Her father has type 1 diabetes. During one such episode, the blood sample collected revealed:<br>Blood glucose: 40 mg/dL<br>Insulin: 1261 pmol/L (elevated)<br>C-peptide: 20 pmol/L (low)<br>Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1186909",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186909,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Whilst insulinoma would be a possibility in a patient with this medical history, the marked elevation in insulin levels in the presence of a low C-peptide suggests that illicit use of insulin is the most likely diagnosis.</p>\n<ul>\n<li>Surreptitious use of insulin or hypoglycemic agents may be difficult to distinguish from an insulinoma.</li>\n<li>Evaluation of proinsulin and C-peptide levels, both of which should be normal in patients using exogenous insulin, and measurement of sulfonylurea levels in serum or plasma are helpful in such cases.</li>\n<li>In the exogenous use of insulin, insulin levels will be very high.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Insulinoma (Option A):</strong> The diagnosis of insulinoma is generally confirmed with elevated fasting insulin levels in conjunction with elevated proinsulin and C-peptide. Hypoglycemic attacks are precipitated by a period of fasting +/- exercise.</p>\n<p><strong>Reactive Hypoglycemia (Option B):</strong> Reactive hypoglycemia occurs due to an exaggerated insulin response following meals. It is usually associated with normal values of proinsulin and C-peptides.</p>\n<p><strong>Illicit use of sulphonylureas (Option C): </strong>Illicit use of sulphonylureas is associated with both higher insulin and c-peptide levels</p>",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">pH < 7.3</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperamylasemia</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Normal anion gap metabolic acidosis</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Pseudohyponatremia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 38-year-old female with diabetes was brought to the ER with recurrent episodes of vomiting and abdominal pain. On examination, she was tachypneic, dehydrated and drowsy with lab investigations showing high blood glucose levels and positive urine ketones. Which of the following is not a feature of her likely diagnosis?</span></p>",
      "unique_key": "DT1186910",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186910,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The clinical presentation is suggestive of diabetic ketoacidosis, and DKA is not characterised by normal anion gap metabolic acidosis.</p>\n<ul>\n<li>The metabolic derangement in Diabetic ketoacidosis is manifested as <strong>high-anion-gap acidosis.</strong></li>\n<li>The accumulation of ketoacids in plasma accounts for the increment in the anion gap in DKA.</li>\n</ul>\n<p><strong>The diagnostic criteria for Diabetic Ketoacidosis:</strong></p>\n<ul>\n<li>pH &lt; 7.3</li>\n<li>Serum bicarbonate &lt; 15 mEq/L</li>\n<li>Ketonuria / Ketonemia (Serum beta-hydroxybutyrate&gt; 3 mmol/L)</li>\n<li>Blood glucose &gt; 250 mg/dl</li>\n</ul>\n<p><strong>Clinical symptoms and signs:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918fd9e5660-1cf0-4944-8609-abee381a533a.png\">\n<p><strong>Laboratory findings:</strong></p>\n<ul>\n<li>High serum blood glucose levels</li>\n<li>Presence of urine ketone bodies</li>\n<li>Raised serum osmolality</li>\n<li><strong>Pseudohyponatremia</strong> (due to raised blood glucose)</li>\n<li>High anion gap metabolic acidosis</li>\n<li><strong>Hyperamylasemia</strong></li>\n<li>Hyperkalemia</li>\n<li>Hyperphosphatemia</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>pH &lt; 7.3 (option A): </strong>Serum ketones are present at significant levels in DKA, explaining the rise in pH. Arterial pH usually ranges between 6.8 and 7.3, depending on the severity of the acidosis.</p>\n<p><strong>Hyperamylasemia (Option B): </strong>Hyperamylasemia may suggest a diagnosis of pancreatitis, especially when accompanied by abdominal pain. However, in DKA, the amylase is usually of salivary origin and thus is not diagnostic of pancreatitis. Serum lipase should be obtained if pancreatitis is suspected.</p>\n<p><strong><strong>Pseudohyponatremia (Option D):</strong> </strong>Pseudohyponatremia occurs in the background of a hyperosmolar solute like glucose, which causes low sodium levels despite the normal serum osmolality. Hyperglycemia causes fluid to shift into the extracellular space, diluting the serum, resulting in pseudohyponatremia.</p>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Start IV fluids and Insulin infusion; Avoid bicarbonates</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Start IV fluids and insulin infusion; Administer bicarbonate at 50 mmol/hr</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Start IV fluids; Give Potassium supplementation; Insulin infusion after K+ correction</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Start IV fluids and potassium supplementation; Start Insulin infusion simultaneously</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An 18-year-old female with Type 1 Diabetes mellitus and poor adherence to treatment presented to the ER with vomiting and abdominal pain. Investigations revealed:<br>GRBS 536 mg/dl<br>pH 7.1<br>Bicarbonate 11 mEq/L,<br>Urine ketones positive<br>Na 130 mEq/L<br>K 3 mEq/L.<br>What of the following is the most appropriate next step in managing her condition?</span></p>",
      "unique_key": "DT1186911",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186911,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The clinical presentation is characteristic of<strong> diabetic ketoacidosis with hypokalemia.</strong></p>\n<p><strong>Management of diabetic ketoacidosis:</strong></p>\n<ul>\n<li>Replace fluids\n<ul>\n<li><strong>Fluid Replacement </strong>is the cornerstone of management.</li>\n<li>2-3 L of 0.9% saline or lactated Ringer's over the first 1-3 h</li>\n<li>Fluid of choice: Normal saline</li>\n</ul>\n</li>\n<li>Administer<strong> short-acting regular insulin</strong>:\n<ul>\n<li>Intravenous insulin 0.1 units/kg per hour is administered by continuous IV infusion</li>\n<li>Dose increased two- to threefold if no response by 2-4 h.</li>\n<li>If the initial serum potassium is &lt;3.3 mmol/L (3.3 meq/L), do not administer insulin until the potassium is corrected.</li>\n<li>When serum glucose reaches 200 mg/dL, reduce regular insulin infusion to 0.02 to 0.05 units/kg/hour IV, or give rapid-acting Insulin at 0.1 units/kg SC every two hours.</li>\n<li>Keep serum glucose between 150 and 200 mg/dL until resolution of DKA.</li>\n</ul>\n</li>\n<li>Check electrolytes, BUN, venous pH, creatinine, and glucose every two to four hours until stable.</li>\n<li>After resolution of DKA and when the patient can eat, initiate SC multidose (basal-bolus) insulin regimen</li>\n<li>Continue IV insulin infusion for two to four hours after SC insulin is begun to ensure adequate plasma insulin levels.</li>\n<li>In insulin na&iuml;ve patients, start at 0.5 to 0.8 units/kg body weight per day, and adjust insulin as needed.</li>\n<li>Look for precipitating cause(s)</li>\n</ul>\n<p><strong>Potassium supplementation in DKA:</strong></p>\n<ul>\n<li>If the initial serum K+ is &lt; 3.3 mEq/L, insulin infusion should be started. Potassium correction should be initiated, and insulin to be started once serum K+ &gt; 3.3 mEq/L <em>(Option A, D ruled out)</em></li>\n<li>If initial K+ &gt; 5.3 mEq/L, insulin therapy can be started without K+ administration. Potassium values to be monitored every 4 hours</li>\n<li>Suppose the initial K+ is between 3.3 and 5.3 mEq/L. In that case, insulin infusion is to be started along with potassium supplementation because ongoing insulin supplementation would result in a lowering of serum K+ due to transcellular shift.</li>\n</ul>\n<p><strong>Bicarbonate supplementation in DKA:</strong></p>\n<p>Given only if PH &lt;7, or else it may develop alkalosis, then hypokalemia <em>(Option B ruled out)</em></p>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Duloxetine</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Pregabalin</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Tapentadol</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Amitriptyline</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old male with 15-year history of Type 2 DM presents with burning pain and tingling sensations in both feet, consistent with peripheral neuropathy. Which of the following is not an FDA-approved drug for Diabetic peripheral neuropathy that can be used for managing his condition?</span></p>",
      "unique_key": "DT1186912",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186912,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Though tricyclic antidepressants like amitriptyline are commonly employed for managing positive symptoms of diabetic neuropathy, they are not FDA-approved.</p>\n<ul>\n<li>Chronic, painful diabetic neuropathy is difficult to treat, with only symptomatic treatment being available; evidence of the effectiveness of improved glycemic control in painful diabetic neuropathy is lacking.</li>\n<li>Two oral agents approved by the U.S. Food and Drug Administration (FDA), <strong>duloxetine</strong> and <strong>pregabalin</strong>, or gabapentin, are usually initially used for pain associated with diabetic neuropathy. <em>(Option A, B ruled out)</em></li>\n<li>Diabetic neuropathy may respond to t<strong>ricyclic antidepressants</strong>, venlafaxine, carbamazepine, tramadol, or topical capsaicin products.</li>\n<li>An 8% capsaicin patch requires application by a health care provider.</li>\n<li><strong>Tapentadol</strong>, a centrally acting opioid, is also approved by the FDA, but has only modest efficacy and poses addiction risk, making it and other opioids less desirable and not a first-line therapy <em>(Option C ruled out).</em></li>\n</ul>",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Gamma cells</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Delta cells</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Zeta cells</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Epsilon cells</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Ghrelin is secreted by:</span></p>",
      "unique_key": "DT1186913",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186913,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>The various cells in Islets of Langerhans and their hormones include:\r\n<ul>\r\n<li>Alpha (A) cells - glucagon</li>\r\n<li>Beta (B) cells - Insulin</li>\r\n<li>Delta (D) cells - Somatostatin</li>\r\n<li>Gamma (F) cells - Pancreatic polypeptide</li>\r\n<li>Epsilon cells - Ghrelin</li>\r\n</ul>\r\n</li>\r\n<li>Beta cells are the most abundant cells in Islet in Langerhans (60%)</li>\r\n</ul>\r\n<p><strong>Reference:</strong> William's textbook of Endocrinology 14<sup>th</sup> edition Page 1338</p>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">GLUT1</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">GLUT2</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">GLUT4</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">SGLT1</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Glucose enters the pancreatic beta cell via:</span></p>",
      "unique_key": "DT1186914",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186914,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>GLUT increases glucose transport by facilitated diffusion</li>\r\n<li>GLUT2 mediates glucose entry into pancreatic beta cells</li>\r\n<li>Other locations for GLUT2 are liver, hypothalamus and renal tubular cells</li>\r\n<li>GLUT4 mediates glucose entry to insulin dependent tissues muscle, adipose tissue and heart</li>\r\n<li>Insulin increases glucose uptake in the liver by increasing glucokinase activity and inhibiting glycogen phosphorylase</li>\r\n<li>SGLT1 is present in intestinal epithelial cells and transports glucose and galactose</li>\r\n<li><strong>Fructose is transporter by GLUT5</strong></li>\r\n</ul>\r\n<p><strong>Reference:</strong> Harrison's Principles of Internal Medicine 21<sup>st</sup> edition page 3098</p>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">FBS more than 100 mg/dl with osmotic symptoms</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">FBS more than 140 mg/dl without osmotic symptoms</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">PPBS more than 140 mg/dl without osmotic symptoms</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">RBS more than 200 mg/dl with osmotic symptoms</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 46-year-old male on routine check-up was found to have elevated blood glucose levels. Which of the following would confirm a diagnosis of Diabetes mellitus?</span></p>",
      "unique_key": "DT1186916",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186916,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Criteria for the diagnosis of diabetes</strong></p>\n<ul>\n<li><strong>FBS &gt;126mg/dl </strong>(7.0 mmol/L). Fasting is defined as no caloric intake for at least 8h.</li>\n<li><strong>2-h PPBS &gt; 200 mg/dL</strong> (11.1 mmol/L) during OGTT. The test should be performed as described by WHO, using a glucose load containing the equivalent of 75g anhydrous glucose dissolved in water.</li>\n<li><strong>HBA1C &gt; 6.5%</strong> (48 mmol/mol). The test should be performed in a laboratory using a method that is NGSP-certified and standardised to the DCCT assay.</li>\n<li>In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a <strong>random plasma glucose &gt; 200 mg/dl </strong>(11.1 mmol/L)</li>\n</ul>\n<p>If any of the above is satisfied, then the diagnosis of diabetes mellitus is made.</p>\n<p><strong>Criteria defining prediabetes:</strong></p>\n<ul>\n<li>FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG)</li>\n</ul>\n<p>Or</p>\n<ul>\n<li>2-h PG during 75g OGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (IGT)</li>\n</ul>\n<p>Or</p>\n<ul>\n<li>HbA1C 5.7 - 6.4% (39 - 47 mmol/mol)</li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<p>WHO criteria for the diagnosis of diabetes mellitus:</p>\n<ul>\n<li>Fasting Blood glucose &gt; 126 mg/dl</li>\n<li>Post-prandial Blood glucose &gt; 200 mg/dl</li>\n<li>Random blood glucose &gt; 200 mg/dl with symptoms</li>\n<li>HBA1C <u>&gt;</u> 6.5</li>\n</ul>",
      "correct_choice_id": 154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased first-phase insulin secretion</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased glucose uptake in muscle</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased hepatic glucose output</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased glucagon levels</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a patient with elevated fasting blood glucose, which of the following represents the main pathophysiology?</span></p>",
      "unique_key": "DT1186917",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186917,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The basic abnormality in increased fasting glucose is high hepatic glucose output, mainly due to reduced basal secretion of insulin or hepatic insulin resistance.</p>\n<ul>\n<li>Type 2 DM is characterised by impaired insulin secretion, insulin resistance, excessive hepatic glucose production, abnormal fat metabolism, and systemic low-grade inflammation.</li>\n<li>In the early stages of the disorder, glucose tolerance remains near-normal, despite insulin resistance, because the pancreatic beta cells compensate by <strong>increasing insulin output</strong>.</li>\n<li>A decline in insulin secretion and/or increased glucagon secretion causes an increase in hepatic glucose production, leading to fasting hyperglycemia.</li>\n<li><strong>Increased hepatic glucose output</strong> predominantly accounts for increased FBS levels, whereas <strong>decreased peripheral glucose utilisation</strong> results in postprandial hyperglycemia.</li>\n</ul>\n<p><strong>Explanation of answer:</strong></p>\n<p><strong>Decreased first-phase insulin secretion (Option A): </strong>In type 2 DM, insulin secretion initially increases in response to insulin resistance to maintain normal glucose tolerance. Initially, the insulin secretory defect is mild and selectively involves glucose-stimulated insulin secretion, including a greatly reduced first secretory phase.</p>\n<p><strong>Decreased glucose uptake in muscle (Option B): </strong>This causes insulin resistance, especially affecting postprandial glucose disposal. It does contribute to hyperglycemia, but not as directly to fasting glucose elevations.</p>\n<p><strong>Increased glucagon levels (Option C): </strong>In diabetes, alpha-cell dysregulation leads to increased glucagon, which stimulates hepatic glucose output. While it contributes to hyperglycemia, the direct cause of increased fasting glucose is the hepatic output itself.</p>",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Increasing gluconeogenesis</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Increasing insulin levels</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduces glycogenesis</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase glucose uptake into muscle</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a pharmacological action of metformin?</span></p>",
      "unique_key": "DT1186918",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186918,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li>Metformin decreases hepatic gluconeogenesis there by reducing insulin levels and also increases insulin sensitivity by enhancing glucose uptake into muscle</li>\r\n<li>The actions of Metformin is mediated via activation of AMP kinase enzyme</li>\r\n<li>Decreased insulin levels lead to reduction in insulin mediated androgen production from the ovary thereby improving signs and symptoms of polycystic ovarian disease</li>\r\n</ul>\r\n<p><strong>Reference:</strong> Harrison's Principles of Internal Medicine 21<sup>st</sup> edition page 3110</p>",
      "correct_choice_id": 174,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic ketoacidosis</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Bladder cancer</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Pedal oedema</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Lower limb amputations</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is an adverse effect associated with the use of Empagliflozin?</span></p>",
      "unique_key": "DT1186919",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186919,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Empagliflozin use is commonly associated with the risk of<strong> diabetic ketoacidosis.</strong></p>\n<ul>\n<li>Empagliflozin belongs to the class of<strong> SGLT 2 inhibitors</strong>.</li>\n<li>Canagliflozin and dapagliflozin are other drugs in this group that are commonly used.</li>\n<li>SGLT 2 inhibitors lower the blood glucose by selectively inhibiting this co-transporter, which is expressed almost exclusively in the proximal, convoluted tubule in the kidney.</li>\n<li>This inhibits glucose reabsorption, lowers the renal threshold for glucose, and leads to <strong>increased urinary glucose excretion</strong>.</li>\n<li>Inhibition of SGLT2 may lead to increased glucagon and, consequently, liver production of glucose and ketones.</li>\n<li><strong>Euglycemic DKA</strong> may occur during illness or when ongoing glucosuria masks stress-induced requirements for insulin.</li>\n<li>These agents should not be prescribed for patients with type 1 DM or pancreatogenic forms of DM associated with insulin deficiency.</li>\n<li>Mechanism by which SGLT-2 inhibitors increase the risk of DKA includes:\n<ul>\n<li>Diuretic effect producing volume contraction</li>\n<li>Hyperglucagonemia</li>\n<li>Non-insulin dependent glucose reduction</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Lower limb amputation (Option D): </strong>These are adverse effects associated with canagliflozin.</p>\n<p><strong>Bladder cancer (Option B): </strong>A possible increased risk of bladder cancer has been seen with dapagliflozin. However, pioglitazone, a thiazolidinedione, is found to be more associated with an increased risk of bladder cancer.</p>\n<p><strong>Pedal oedema (Option C): </strong>SGLT 2 inhibitors use is associated with a diuretic effect and a 3-6 mmHg reduction in systolic blood pressure. Peal edwema is associated with the use of thiazolidinediones, which causes a reduction in the hematocrit and a mild increase in plasma volume.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509189132633a-4d23-40a7-a94f-f2f4ddca91d5.png\">\n<p><strong>Key Takeaway:</strong></p>\n<p>SGLT-2 inhibitors increase the risk of diabetic ketoacidosis.</p>",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Intravenous antibiotics</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Intravenous bicarbonate</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Intravenous fluids</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Intravenous insulin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 22-year-old young woman with poorly controlled diabetes mellitus presents with a temperature, dehydration and altered consciousness. On evaluation, her laboratory investigations revealed the following findings:<br>Na+ 130 mmol/l, K+ 4.5 mmol/l<br>Bicarbonate 6 mmol/l,<br>Hydrogen ion concentration 80 nmol/L<br>What is the most crucial immediate step in her management?</span></p>",
      "unique_key": "DT1186920",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186920,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient is presenting with <strong>diabetic ketoacidosis</strong>. The most crucial initial intervention is <strong>intravenous fluid resuscitation with normal saline</strong>, as <strong>hypovolemia</strong> is the factor most likely to cause mortality.</p>\r\n<ul>\r\n<li><strong>Diabetic ketoacidosis is </strong>a condition associated with an increased risk of mortality in patients with type 1 diabetes mellitus.</li>\r\n<li>In DKA, there is a total body deficit of fluid and electrolytes.</li>\r\n<li>Hypotension and hypovolemia result from <strong>severe osmotic diuresis</strong>.</li>\r\n<li><strong>Aggressive fluid replacement</strong> becomes essential and is the cornerstone of the management of DKA.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Intravenous antibiotics (Option A): </strong>Infections can precipitate diabetic ketoacidosis. Though fever necessitates the need to rule out infections and start IV antibiotics, it is not the first-line management in DKA.</p>\r\n<p><strong>Intravenous bicarbonate (Option B):</strong> Although bicarbonates &lt; 7 mmol/L indicate the need for bicarbonate administration, intravenous bicarbonate should not be used immediately as it can cause massive fluid shifts and precipitate cerebral oedema.</p>\r\n<p><strong>Intravenous insulin (Option D):</strong> IV insulin is required to lower the blood glucose levels. But insulin should be started immediately in the background of severe hypotension, as insulin can further worsen hypovolemia and hypoperfusion. Also, insulin causes potassium to shift intracellularly, risking <strong>severe hypokalemia</strong> if potassium is not corrected or monitored.</p>\r\n<p><strong>Management of diabetic Ketoacidosis:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918ca4385ed-793c-4d36-8b50-f01d8b170df7.png\">",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">GNRH concentration</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral glucose tolerance test with growth hormone measurement</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">IGF-1 measurement</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">IGFBP-3 measurement</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old man presents with new-onset Type 2 diabetes mellitus. He complains of swollen fingers and increased jaw prominence over the past few years. On evaluation, his BP is 152/90 mmHg, and fasting blood glucose is 165 mg/dl. Which of the following is the most appropriate initial screening test for the likely underlying condition?</span></p>",
      "unique_key": "DT1186921",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186921,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>New-onset T2DM, hypertension, swollen fingers and prominence of facial features are classic signs of acromegaly, typically caused by a pituitary adenoma which secretes an excess of IGF-1.</p>\n<ul>\n<li>Diabetes mellitus develops in 25% of patients with acromegaly, as GH counteracts the action of insulin.</li>\n<li>Growth hormone stimulates the production of IGF-1; age-matched serum IGF-1 levels are elevated in acromegaly.</li>\n<li>Consequently, an IGF-1 level provides a useful laboratory screening measure when clinical features raise the possibility of acromegaly.</li>\n<li>Due to the pulsatility of GH secretion, measuring a single random GH level is not useful for diagnosing or excluding acromegaly and does not correlate with disease severity.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>GnRH concentration (Option A): </strong>GnRH (gonadotropin-releasing hormone) regulates reproductive hormones and is not directly involved in the diagnosis of acromegaly. While large pituitary tumours can affect gonadotropins and sex steroid levels due to mass effect, assessing GnRH is not relevant for initial evaluation or diagnosis of acromegaly.</p>\n<p><strong>Oral glucose tolerance test with growth hormone measurement (Option B): T</strong>he 75g OGTT is a sensitive diagnostic test for acromegaly. In healthy individuals, glucose suppresses growth hormone secretion; in acromegaly, this suppression fails, confirming the diagnosis. Some patients exhibit a paradoxical rise in GH after glucose administration, which further supports the diagnosis.</p>\n<p><strong>IGFBP-3 measurement (Option D): </strong>IGFBP-3 is the main circulating binding protein for IGF and may be of utility in the future as a screening test for acromegaly.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250918f131d521-d52f-4c20-bc8b-b635ee6d3350.png\">\n<p><strong>Key Takeaway:</strong></p>\n<p><strong>Acromegaly:</strong></p>\n<ul>\n<li>Initial Screening Test: Serum IGF-1 (Insulin-like Growth Factor 1) level</li>\n<li>Gold Standard confirmatory test: Oral Glucose Tolerance Test (OGTT)</li>\n</ul>",
      "correct_choice_id": 203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Glimepiride</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Linagliptin</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Pioglitazone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 61-year-old post-menopausal woman with type 2 DM on OHA presents with low back pain. Imaging showed a vertebral compression fracture; she also reported a recent history of wrist fractures. Which of the following oral anti-hyperglycemic drugs is most likely responsible for her condition?</span></p>",
      "unique_key": "DT1186922",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186922,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Pioglitazone causes osteoporosis, increasing the risk of fractures and is hence usually not preferred in post-menopausal women.</p>\n<ul>\n<li><strong>Pioglitazone</strong> belongs to the thiazolidinediones group of OHAs</li>\n<li>Thiazolidinediones <strong>reduce insulin resistance</strong> by binding to the <strong>PPAR-&gamma; </strong>nuclear receptor, which forms a heterodimer with the retinoid X receptor.</li>\n<li>Important adverse effects include:\n<ul>\n<li>Weight gain and fluid retention</li>\n<li>Decrease in hematocrit (dilution effect)</li>\n<li>Osteoporosis (increased risk of fractures - not preferred in post-menopausal females)</li>\n<li>Risk of bladder cancer</li>\n</ul>\n</li>\n<li>Contraindicated in cardiac and hepatic failure</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Metformin (Option A):</strong> Metformin use is commonly associated with increased incidence of lactic acidosis and Vitamin B12 deficiency.</p>\n<p><strong>Glimepiride (Option B): </strong>Glimepiride is an insulin secretagogues that interact with the ATP-sensitive K+ channel to stimulate insulin secretion. These are mostly associated side effects, like weight gain and hypoglycemia.</p>\n<p><strong>Linagliptin (Option C):</strong> Dipeptidyl peptidase IV inhibitors like linagliptin are associated with angioedema and immune-mediated dermatologic effects.</p>",
      "correct_choice_id": 214,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Pioglitazone should be started in patients post-myocardial infarction</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin should be stopped in all patients post-myocardial infarction</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin should be stopped in patients in patients who have an unstable circulation post infarct</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin should be given IV for the first 48 hours</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 54-year-old man with diabetes is being hospitalised for an acute myocardial infarction. Which of the following is the most appropriate recommendation regarding oral glucose-lowering therapy in the post-infarct period?</span></p>",
      "unique_key": "DT1186923",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186923,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Metformin should be discontinued in hospitalised patients and those with significant circulatory impairment.</p>\n<ul>\n<li>Long-term use of metformin is associated with reduced micro- and macrovascular complications.</li>\n<li>Metformin should not be used in patients with moderate renal insufficiency (GFR &lt;30 mL/min), any form of acidosis, unstable congestive heart failure, liver disease, or severe hypoxemia.</li>\n<li>In patients who have suffered MI, unless there is evidence of significant circulatory impairment or raised creatinine, metformin is continued. <em>(Option B ruled out.)</em></li>\n<li>Metformin should be discontinued in hospitalised patients, in patients who can take nothing orally, and in those receiving radiographic contrast material.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Pioglitazone should be started in patients post-myocardial infarction (Option A): </strong>Glitazones are generally not used in patients post-myocardial infarction because they can cause <strong>fluid retention and worsen heart failure</strong>, which is a concern post-MI.</p>\n<p><strong>Insulin should be given IV for the first 48 hours (Option D).</strong> In hospital settings, usually for hyperglycemic control, insulin is advised. However, continuous glucose monitoring will be needed to prevent the risk of hypoglycemia.</p>",
      "correct_choice_id": 223,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Discontinue metformin during the fasting period</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Initiate short-acting insulin with the evening meal</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Switch to glicazide BD</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Give metformin 500mg in the morning, 1000mg in the evening</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old male with type 2 diabetes has a habit of fasting for religious rituals. He has a background of diabetic retinopathy and is currently taking metformin 500 mg thrice daily, along with ramipril 10 mg and aspirin 75 mg. His recent HbA1c is 7.8%. Laboratory investigations are within normal limits. What is the most appropriate adjustment to his diabetes medication during the fasting period?</span></p>",
      "unique_key": "DT1186924",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186924,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Metformin is not associated with hypoglycaemia when used as monotherapy.</li>\n<li>Metformin, when taken three times a day, the midday dose (which coincides with fasting) may not be appropriate.</li>\n<li>Recommended dose adjustment would be <strong>500 mg in the morning and 1000 mg along with the evening meal.</strong></li>\n<li>Metformin <strong>reduces hepatic glucose output </strong>and has its predominant effects on fasting plasma glucose.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Discontinue metformin during the fasting period (Option A): </strong>Metformin should not be stopped entirely, especially in a patient with an HbA1c of 7.8% as it indicates suboptimal control. It does not cause hypoglycemia, so it's considered safe during fasting. The goal is dose adjustment, not cessation.</p>\n<p><strong>Initiate short-acting insulin with the evening meal (Option B):</strong> Giving short-acting insulin or switching to insulin is likely to increase the risk of hypoglycaemia.</p>\n<p><strong>Switch to glicazide BD (Option C): </strong>Gliclazide, which is an insulin secretagogue which carries a higher risk of hypoglycemia, especially if taken during fasting hours. Hence is not advisable for this patient during fasting.</p>",
      "correct_choice_id": 234,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}